Zentalis Pharmaceuticals Grants Inducement Shares to New Hires

Biotech firm awards stock options to two new employees under Nasdaq rules.

Apr. 2, 2026 at 7:20am

Got story updates? Submit your updates here. ›

Zentalis Pharmaceuticals, a clinical-stage oncology company, announced that it has granted non-qualified stock options to purchase a total of 36,000 shares of the company's common stock to two newly hired employees. The stock options were awarded under Zentalis' 2022 Employment Inducement Incentive Award Plan as an inducement for the individuals to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters

Inducement grants like these are common practice for public companies to attract top talent, especially in competitive industries like biotech. The grants align the new hires' interests with those of shareholders by providing equity incentives tied to the company's future performance.

The details

The stock options have an exercise price of $2.57 per share, which matches the closing price of Zentalis' stock on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the following three years. Vesting is contingent on the employees' continued service to Zentalis.

  • Zentalis granted the stock options on April 1, 2026.

The players

Zentalis Pharmaceuticals, Inc.

A clinical oncology company developing a treatment approach for ovarian cancer and multiple tumor types, including a first-in-class WEE1 inhibitor called azenosertib.

2022 Employment Inducement Incentive Award Plan

A stock option plan used by Zentalis exclusively to grant equity awards to new hires as an inducement to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Got photos? Submit your photos here. ›

The takeaway

Zentalis' use of inducement grants highlights the competitive landscape in biotech, where companies must offer attractive equity incentives to recruit top scientific and clinical talent. These types of awards aim to align new hires' interests with long-term shareholder value creation.